MZL and Ibrutinib

Research is underway in some of the smaller subtypes of lymphoma. This phase II, open label non-randomised study is evaluating the safety and efficacy of ibrutinib in those with relapsed or refractory marginal zone lymphoma.

Patients (n = 60) will be enrolled from approximately 32 sites in Belgium, France, Germany, the UK and the USA. Please let your members know about this clinical trial. For more information, click here to read the full article.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.